Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. (March 2018)

• Record Type: Journal Article
• Authors: Lernoux, Manon; Schnekenburger, Michael; Dicato, Mario; Diederich, Marc
• Is Part Of: Pharmacological research. Volume 129(2018)
• Page Start: 337
• Page End: 356
• Publication Date: 2018-03
• Subjects: FK228 (PubChem CID: 5352062) -- PXD101 (PubChem CID: 6918638) -- SAHA (PubChem CID: 5311) -- LBH-589 (PubChem CID: 6918837) -- tubacin (PubChem CID: 6675804) -- tubastatin A (PubChem CID: 49850262) -- ACY-1215 (PubChem CID: 53340666) -- ACY-241 (PubChem CID: 53340426) -- (−)-epigallocatechin-3-gallate (PubChem CID: 65064) -- aceroside VIII (PubChem CID: 21637600) -- curcumin (PubChem CID: 969516) -- ellagic acid (PubChem CID: 5281855) -- genistein (PubChem CID: 5280961) -- 20(S)-Rh2 (PubChem CID: 119307) -- salirepol (PubChem CID: 188287) -- butyrate (PubChem CID: 264) -- sulforaphane (PubChem CID: 5350) -- trichostatin A (PubChem CID: 444732) -- ursodeoxycholic acid (PubChem CID: 31401) -- ursolic acid (PubChem CID: 64945); ALL acute lymphoblastic leukemia -- AML acute myeloid leukemia -- AP activator protein -- AR androgen receptor -- BAX Bcl-2-associated X protein -- Bcl B-cell lymphoma -- BUZ ubiquitin-binding domain -- CDK cyclin-dependent kinase -- CLIP cytoplasmic linker protein -- CLL chronic lymphocytic leukemia -- CTCL cutaneous T-cell lymphoma -- CYLD cylindromatosis -- DD deacetylase domain -- DMB dynein motor binding -- DNMT DNA methyltransferase -- EA ellagic acid -- EB end binding protein -- EC endothelial cell -- EGCG (−)-epigallocatechin-3-gallate -- EGFR epidermal growth factor receptor -- EMT epithelial-to-mesenchymal transition -- ER estrogen receptor -- ERK extracellular signal-regulated kinase -- ERST endoplasmic reticulum stress-tolerance -- FADD Fas-associated protein with death domain -- FDA Food and Drug Administration -- FLICE FADD-like IL-1 β-converting enzyme -- FLIP FLICE inhibitory protein -- GBM glioblastoma -- GR glucocorticoid receptor -- GSK glycogen synthase kinase -- HAT histone acetyltransferase -- HCC hepatocellular carcinoma -- HDAC histone deacetylase -- HDAC6i HDAC6 inhibitor -- HDACi HDAC inhibitor -- HIF hypoxia-inducible factor -- HMGN high mobility group nucleosomal binding domain -- HSF heat shock transcription factor -- HSP heat shock protein -- ICD immunogenic cell death -- IIp invasion inhibitory protein -- IL interleukin -- JAK Janus kinase -- LCoR ligand-dependent nuclear receptor co-repressor -- MAPK mitogen-activated protein kinase -- MM multiple myeloma -- MMP matrix metalloproteinase -- MST mammalian STE20-like kinase -- MT microtubule -- mTOR mammalian target of rapamycin -- NES nuclear export signal -- NLS nuclear localization signal -- Nrf nuclear factor erythroid 2-related factor -- PI3K phosphoinositide 3-kinase -- PKA protein kinase A -- PP protein phosphatase -- Prx peroxiredoxin -- PTEN phosphatase and tensin homolog -- PTM post-translational modification -- RhoB Ras homolog family member B -- RUNX runt-related transcription factor -- SAHA suberoylanilide hydroxamic acid -- SE14 cytoplasmic retention domain -- SFN sulforaphane -- SIRT sirtuin -- SMRT silencing mediator for retinoid or thyroid-hormone receptor -- SRSF serine and arginine rich splicing factor -- STAT signal transducer and activator of transcription -- Tau tubule-associated unit -- TGF transforming growth factor -- TPA 12-O-tetradecanoylphorbol-13-acetate -- TPPP tubulin polymerization-promoting protein -- TSA trichostatin A -- TSG tumor suppressor gene -- UA ursolic acid -- UDCA ursodeoxycholic acid -- VCP valosin-containing protein -- VEGF vascular endothelial growth factor -- VEGFR VEGF receptor -- ZBG zinc binding group; HDAC6 -- HDAC6 inhibitors -- Natural compounds -- Cancer hallmarks -- Cancer therapy; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2017.11.004
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Alterations of the epigenetic machinery, affecting multiple biological functions, represent a major hallmark enabling the development of tumors. Among epigenetic regulatory proteins, histone deacetylase (HDAC)6 has emerged as an interesting potential therapeutic target towards a variety of diseases including cancer. Accordingly, this isoenzyme regulates many vital cellular regulatory processes and pathways essential to physiological homeostasis, as well as tumor multistep transformation involving initiation, promotion, progression and metastasis. In this review, we will consequently discuss the critical implications of HDAC6 in distinct mechanisms relevant to physiological and cancerous conditions, as well as the anticancer properties of synthetic, natural and natural-derived compounds through the modulation of HDAC6-related pathways.